U.S. Markets closed

Zacks Bull and Bear of the Day Highlights: Eastman Chemical, GlaxoSmithKline, Staples, Office Depot and OfficeMax


For Immediate Release

Chicago, IL – August 14, 2012 – Zacks Equity Research highlights Eastman Chemical Co. (EMN) as the Bull of the Day and GlaxoSmithKline, plc (GSK) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Staples Inc. (SPLS), Office Depot Inc (ODP) and OfficeMax Inc (OMX).


Full analysis of all these stocks is available at http://at.zacks.com/?id=2678.

Here is a synopsis of all five stocks:

Bull of the Day:

We are reaffirming our Outperform recommendation on Eastman Chemical Co. (EMN). Second quarter adjusted earnings topped the Zacks Consensus Estimate while sales missed. However, the company continues to expect double-digit earnings growth in 2012.

We believe that Eastman Chemical is well placed to benefit in the second half from the synergies of the Solutia acquisition. The company's diversified chemical portfolio, along with its integrated and diverse downstream businesses, is driving its earnings. It also benefits from business restructuring, cost-cutting measures and increased capacity additions.

On a P/E basis, the stock is trading at a discount to the peer group. Our long-term Outperform recommendation indicates that it will perform above the broader market. Our price target of $65 is based on 12.5x our fiscal 2012 earnings estimate.


Bear of the Day:


GlaxoSmithKline, plc's (GSK) second quarter earnings of $0.79 per ADS were below the Zacks Consensus Estimate of $0.84. Earnings fell 2.5% year over year. Revenues fell 7.3% y/y to $10.2 billion, missing the Zacks Consensus Estimate of $10.4 billion.

Glaxo expects 2012 revenues to remain flat y/y (at CER). Earlier, Glaxo was expecting revenues to grow from 2011 levels. Guidance was lowered due to EU pricing pressure. A major part of Glaxo's revenues will be exposed to generic competition as multiple drugs are scheduled to lose exclusivity in the next few years. We expect the company's top line as well as gross margins to remain under pressure in the coming quarters.

In addition to generic competition, US health care reform and EU pricing pressure will continue to affect sales. Thus, we maintain our Underperform recommendation on Glaxo, which carries a Zacks #4 Rank (short-term Sell rating).



Latest Posts on the Zacks Analyst Blog:


Earnings Preview: Staples


Staples Inc. (SPLS), a leading retailer of office products and services, is slated to report its second-quarter 2012 financial results on August 15, 2012. The current Zacks Consensus Estimate for the quarter stands at 22 cents per share (flat when compared with the prior-year quarter) on revenues of $5.73 billion.

First-Quarter Recap

Staples, which competes with Office Depot Inc (ODP) and OfficeMax Inc (OMX), posted quarterly earnings of 30 cents a share in the first quarter, in line with the Zacks Consensus Estimate and up 7.1% from 28 cents earned in the prior-year quarter. Including one-time items, earnings decreased 3.6% year over year to 27 cents.

Staples reported total sales of $6.1 billion, down 1.1% year over year. Sales marginally missed the Zacks Consensus Estimate of $6.2 billion.

Management expects sales to increase in the low single digits in fiscal 2012, while the bottom line is expected to augment in the high single digits.

Agreement of Estimate Revisions

Over the past 30 days, 4 out of 14 estimates have been revised downwards, while none were raised for the second quarter. Moreover, for fiscal 2012, 5 out of 16 estimates have been revised in the downward direction, while none moved in the opposite direction.   

The analysts believe that the challenging macro economic outlook continues to remain a drag on the company’s results as the sector’s performance is closely related to the health of the economy.  Further, Staples’ significant exposure to the European market remains a matter of concern.

Magnitude of Estimate Revisions

Given the downward estimate revisions, the Zacks Consensus Estimate for fiscal 2012 came down by a couple of cents to $1.47 in the last 30 days. The Zacks Consensus Estimate remained stable for the upcoming quarter.

Surprise History

With respect to earnings surprises, Staples surpassed as well as met the Zacks Consensus Estimate over the last four quarters in the range of 0% to 10%. The average remained at 10%, indicating that the company has outperformed the Zacks Consensus Estimate consistently over the trailing four quarters.

Our Take

Being a leading retailer of office products and services, Staples is better positioned than its competitors to sustain growth based on its margin expansion, effective merchandising, and growth prospects across its retail, delivery and international divisions.

However, we remain concerned regarding the company’s International segment, which is suffering from declining sales.

Currently, we have a long-term “Neutral” recommendation on the stock. Moreover, Staples holds a Zacks #3 Rank that translates into a short-term “Hold” rating. 



Get the full analysis of all these stocks by going to http://at.zacks.com/?id=2649.



About the Bull and Bear of the Day


Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.


About the Analyst Blog


Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.


About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.


Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=7158.


About Zacks


Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment

Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4582.


Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.


Follow us on Twitter:  https://twitter.com/zacksresearch


Join us on Facebook:  https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts


Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.


Media Contact
Zacks Investment Research

800-767-3771 ext. 9339



Read the analyst report on EMN

Read the analyst report on GSK

Read the analyst report on SPLS

Read the analyst report on ODP

Read the analyst report on OMX

Zacks Investment Research

More From Zacks.com